Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1299 Vaccine +/- Cyclophosphamide and Celecoxib in Thoracic Malignancies
NCT02054104Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of H1299 lysate vaccine in thoracic cancer, sarcoma, melanoma, sponsored by National Cancer Institute. Started Sep 2014; status: terminated.
02
Drugs
H1299 lysate vaccine
03
Conditions
thoracic cancersarcomamelanoma
Beyond the preview
Go deeper on NCT02054104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054104.